25 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.
1 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” This Patent Highlight discusses recent progress in developing TYK2 inhibitors, which show potential for treating conditions like cancer, alopecia areata, and psoriatic arthritis.
61 citations
,
December 2021 in “Frontiers in Cell and Developmental Biology” This review discusses progress in targeted therapies for vitiligo, focusing on Janus kinase inhibitors and the potential of mesenchymal stem cells, but reports no new clinical results.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.
December 2021 in “Figshare” This review discusses recent advancements in targeted therapies for vitiligo, including JAK inhibitors and mesenchymal stem cells, and highlights the need for further research.
